Orthocell Issues New Shares on Exercise of Performance Rights

Orthocell Ltd ( (AU:OCC) ) has provided an update.

Orthocell Limited has issued 217,742 fully paid ordinary shares for nil consideration following the exercise of an equivalent number of short‑term performance rights expiring in November 2027, and has confirmed that the issue was conducted without a disclosure document under the relevant Corporations Act provisions. The company stated it is compliant with its continuous disclosure and financial reporting obligations and that there is no excluded information to disclose, signalling a routine capital structure adjustment with no additional material information flagged for investors at this time.

The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

More about Orthocell Ltd

Orthocell Limited is an Australian regenerative medicine company focused on restoring mobility through products that repair bone and soft tissue injuries. Its portfolio includes collagen-based medical devices for dental and orthopaedic reconstruction, such as Striate+™ for dental guided bone regeneration, which is cleared in major markets including the US, Europe and Australia and distributed globally by BioHorizons. Orthocell also markets Remplir™ for peripheral nerve reconstruction, recently cleared in the US and approved in several other countries, and SmrtGraft™ for tendon repair, currently available in Australia via special access or clinical trials. The company is additionally advancing autologous cell therapies targeting tendon and cartilage regeneration, with US-focused development and FDA engagement underway.

Average Trading Volume: 812,156

Technical Sentiment Signal: Buy

Current Market Cap: A$290.1M

For a thorough assessment of OCC stock, go to TipRanks’ Stock Analysis page.